Autoimmune diseases afflict a significant portion of the US population, with the most common age of onset being during young adulthood leading to increased morbidity, early mortality and accrual of damage with associated disability, oftentimes early in life. Many of the systemic autoimmune diseases are characterized by a waxing and waning, or relapsing/remitting, course. These periods of increased disease activity, oftentimes with permanent organ-damage, are interspersed on a background of clinical suppression or quiescence. Although shared across many of the systemic autoimmune diseases, the mechanisms or predictors of disease flares are very poorly understood or not understood at all. This application will focus on understanding mechanisms of disease flare in SLE and then collaborating with other ACE centers, to expand these studies and evaluate which of these mechanisms are common across a number of autoimmune diseases or are disease specific. Over the past funding cycle, our Oklahoma ACE has established and expanded a number of patient collections which have provided insights or samples which will be relevant to understanding mechanisms of SLE disease flare. In preliminary studies of European American SLE patients who exhibited a disease flare within 6 or 12 weeks of baseline assessment compared to patients who did not flare, alterations in 27 soluble mediators {p<0.01) were found at baseline compared to non-flare patients, with significantly higher levels of pro-inflammatory mediators several weeks before clinical flare. Regulatory cytokines were increased at baseline in non-flare SLE patients. Nearly all of these abnormalities were also found in the SLE patients during their flare year compared to samples from these individuals in a non-flare year. Based upon these and other presented preliminary data, we hypothesize that critical alterations in cellular activation, TNF receptor shedding, innate and adaptive mediators of inflammation, and regulatory immune cell pathways are present immediately preceding SLE disease flare. We will test these hypotheses through the following specific aims: 1) determine alterations in innate and adaptive immune cell populations, functional responses and serologic biomarkers in SLE patients immediately before flare compared to matched SLE patients who do not flare, as well as in longitudinal samples;2) evaluate parent cellular populations, levels, locations and functional consequences of shed TNF and other immune receptors in SLE patients temporally preceding a clinical disease flare;and 3) assess the frequency and function of regulatory B and T cells temporally preceding SLE disease flare.

Public Health Relevance

Autoimmune diseases affect 5-7% of the population and often have has periods of disease flares interspersed with disease suppression. This project aims to identify mechanisms responsible for disease flare and predictors of disease flare that are currently unknown or poorly understood to help aid earlier diagnosis, design appropriate clinical trials, develop new directed therapeutic agents and help guide therapy selection to improve the lives of patients with autoimmune diseases.

Agency
National Institute of Health (NIH)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19AI082714-06
Application #
8732896
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Fayyaz, Anum; Kurien, Biji T; Scofield, R Hal (2016) Autoantibodies in Sjögren's Syndrome. Rheum Dis Clin North Am 42:419-34
Arriens, Cristina; Chen, Sixia; Karp, David R et al. (2016) Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol :
Ward, Julie M; Ratliff, Michelle L; Dozmorov, Mikhail G et al. (2016) Expression and methylation data from SLE patient and healthy control blood samples subdivided with respect to ARID3a levels. Data Brief 9:213-9
Sandhya, Pulukool; Kurien, Biji Theyilamannil; Danda, Debashish et al. (2016) Update on Pathogenesis of Sjögren's syndrome. Curr Rheumatol Rev :
Young, Kendra A; Munroe, Melissa E; Guthridge, Joel M et al. (2016) Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus. Ann Rheum Dis :
Lu, Rufei; Munroe, Melissa E; Guthridge, Joel M et al. (2016) Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun 74:182-193
Alarcón-Riquelme, Marta E; Ziegler, Julie T; Molineros, Julio et al. (2016) Genome-Wide Association Study in an Amerindian Ancestry Population Reveals Novel Systemic Lupus Erythematosus Risk Loci and the Role of European Admixture. Arthritis Rheumatol 68:932-43
Liu, Ke; Kurien, Biji T; Zimmerman, Sarah L et al. (2016) X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. Arthritis Rheumatol 68:1290-300
Ward, Julie M; Ratliff, Michelle L; Dozmorov, Mikhail G et al. (2016) Human effector B lymphocytes express ARID3a and secrete interferon alpha. J Autoimmun 75:130-140
Harris, Valerie M; Sharma, Rohan; Cavett, Joshua et al. (2016) Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. Clin Immunol 168:25-9

Showing the most recent 10 out of 105 publications